Lumida
/CGEM
⌘K
Cullinan Therapeutics Inc

Cullinan Therapeutics Inc

CGEM
$20.59USD-1.95%-0.41 today

MARKET CAP

1.3B

P/E (TTM)

FWD P/E

DAY RANGE

$20 – $21

52W RANGE

$6
$23

AI Summary

Stalk
StalkMedium

CGEM is in a Stage 2 advancing structure, supported by a Bearish Exhaustion pattern suggesting sellers are losing control. However, the recent pullback through the rising 9 and 20 EMAs signals weakening short-term momentum. Price remains above the rising 50 SMA and 200 DMA, and RSI and Options Score are neutral, offering no immediate timing edge. Execution should be deferred until a shallow pullback is absorbed at the dynamic EMA support zone, confirming continued trend validity. A decisive close below the 50 SMA would invalidate the medium-term bullish bias.

  • Phase 3 trial for zipalertinib in NSCLC met primary PFS endpoint.
  • Six analysts rate CGEM a Buy with an average price target of $32.14.
  • Deep losses: adjusted Q2 EPS of –$0.81 vs –$0.80 estimate.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021TREND
Sales, Adj.$18.9M
YoY %
P / Sales35.1x
EV / Sales32.6x
Gross Profit, Adj.$18.9M
YoY %
Margin %100.0%
EV / Gross Profit32.6x
EBITDA, Adj.$-64.8M
YoY %
Margin %-342.1%
EV / EBITDA-9.5x
EBIT$-68.0M
YoY %
Margin %-358.7%
EV / EBIT-9.1x
Net Income$-65.6M
YoY %
Net Margin-346.1%
EPS (GAAP)-$1.52
YoY %